ANTIBODIES TO HUMAN IFN IN JPL PATIENTS TREATED WITH HUMAN IFN

135例人白细胞α治疗患者血清标本分析 干扰素(胡干扰素(Le)(纽约血液中心，纽约州梅尔维尔))为 幼年性喉乳头状瘤(J.L.P.)进行了现场测试 上述α干扰素的中和抗体。 11个样本被发现含有阿尔法中和抗体 来自纽约不列颠哥伦比亚州的干扰素。其中10种含有中和作用 抗人白细胞α干扰素抗体(干扰素 科学，新泽西州新不伦瑞克)九株含有中和抗体 重组α干扰素(内含子A，先灵葆雅，凯尼尔沃思， 新泽西州)。没有一种样品能与Alferon或Intron结合 在酶联免疫吸附试验中。然而，Six确实与Wellferon(Burroughs)绑定 韦尔科姆，英国贝肯汉姆)这是一种天然的淋巴母细胞干扰素。 由于我们在实验室中使用Wellferon作为 开始的材料，我们有兴趣确定是否有 阳性样品与我们纯化的成分的结合。我们发现了一个 三个样品与含有以下物质的洗脱液的低水平结合 其中两个物种。尽管上述物种的数量 是一个限制因素，我们正在进行分析，这将 显示存在的抗体是否与其中一种或两种发生反应 组件。

Serum samples from 135 patients treated with human leukocyte alpha interferon (Hu IFN (Le) (New York Blood Center, Melville, N.Y. ) for Juvenile Laryngeal Papillomatosis (J.L.P.) were tested for the presence of neutralizing antibodies to the above mentioned alpha interferon. Eleven samples were found to contain neutralizing antibodies to alpha interferon from the N.Y.B.C. Ten of these contained neutralizing antibodies to Human leukocyte alpha interferon (Alferon; Interferon Sciences, New Brunswick, N.J.) and nine contained neutralizing antibodies to recombinant alpha interferon (Intron A, Schering-Plough, Kenilworth, N.J.). None of the samples were seen to bind to either Alferon or Intron in ELISA assays. Six, however, did bind to Wellferon (Burroughs Wellcome, Beckenham, U.K.) which is a natural lymphoblastoid interferon. Since we purify IFN-a components in our laboratory using Wellferon as starting material, we were interested to determine if there was any binding of the positive samples to our purified components. We found a low level of binding by three of the samples to an eluate which contains two of the species. Although the quantity of the aforementioned species is a limiting factor, we are in the process of running assays which will show if the antibody present reacts with one or both of these components.